Radiometric MICs of clarithromycin, a new macrolide drug, were determined against five mycobactindependent strains of Mycobacterium paratuberculosis (including two Crohn's disease clinical isolates) and compared with those of other drugs which included rifampin, ethambutol, amikacin, ofloxacin, ciprofloxacin, and sparfloxacin. Among the drugs screened, clarithromycin was the drug for which MICs were lowest against the five strains tested. As MICs were significantly below the reported C.. levels (about 4 ,ug/ml), the intracellular activity of clarithromycin against the type strain of M. paratuberculosis maintained in cultured macrophages was screened. Clarithromycin was able to kill the initial inoculum by more than 1 log within 7 days, and this activity was further potentiated by ethambutol. Extracellular drug combination screened by using sublethal concentrations of the drugs showed that ethambutol was able to enhance clarithromycin activity in (20, 25) .
Chemotherapeutic efforts to treat Mycobactenium paratuberculosis, the etiologic agent of paratuberculosis (Johne's disease) in ruminants, have failed to clear animals of the infection (2) . Recently, mycobacteria isolated from human cases of chronic granulomatous ileocolitis of unknown etiology (Crohn's disease) have been found to be genetically identical to M. paratuberculosis (9) . DNA-DNA hybridization studies have established that M. paratuberculosis (including the Crohn's disease isolates), and M. avium belong to a single genomic group (20, 25) .
Similarities between the pathogenesis of M. avium complex (MAC) infections in AIDS, Johne's disease of ruminants, and Crohn's disease in humans, all of which are contracted by the fecal-oral route and involve the gastrointestinal tract, have been underlined (3, 10, 21) . These observations, as well as recent suggestions that M. paratuberculosis may be etiologically involved in human disease (1) , prompted us to examine comparative in vitro activities of antituberculous drugs against M. paratuberculosis.
Among the macrolides, the newer erythromycin derivative clarithromycin, which possesses a methyl group at C-6 (6), was shown to be highly active against multiple-drug-resistant MAC organisms (4, 11, 15, 17, 24 ethambutol, which decreases the MAC cell wall barrier by disrupting the wall outer layer (16) by inhibiting both the biosynthesis of arabinogalactan (23) and the transfer of mycolic acids in the mycobacterial cell envelope (22) , was also investigated. The drug combinations were also tested at sublethal concentrations by using Bactec radiometric methodology to correlate the drug enhancement results obtained using extracellular and intracellular systems used.
The mycobactin-dependent M. paratuberculosis strains used in this investigation (see Table 1 (15, 17, 18) , except that the commercially available 12B vials were supplemented with 2 ,ug of mycobactin-J per ml because of the mycobactin dependence of these strains (Fig. 1) . Parallel experiments in the case of the type strain of M. paratuberculosis (ATCC 19698) showed that the strain grew extremely slowly in the 7H12 broth without mycobactin-J, with MICs interpretable only after 21 days. Although MICs of the drugs did not change in mycobactin-supplemented medium, the data were interpretable at least 1 week earlier.
The combined drug action against M. paratuberculosis was studied radiometrically as reported previously, using the XIY quotient methodology (16-18). For these studies, all the drugs were used at sublethal concentrations as indicated in the figure legends. In accordance with our experimental model for determin- ing the intracellular action of drugs (17-19), drugs were used at their reported Cma. in humans, i.e., 4 pg/ml for clarithromycin (7) and 6 ,ug/ml for ethambutol (8) . Sparfloxacin (Rh6ne-D.P.C. Europe, Antony, France), clarithromycin (Abbott Laboratories, North Chicago, Ill.), amikacin (Bristol, Paris, France), ethambutol (Lederle, Oullins, France), ofloxacin (Laboratoire Diamant, Puteaux, France), and ciprofloxacin (Bayer Pharma, Puteaux, France), were kindly provided by their manufacturers, whereas rifampin was purchased from Sigma Chemical Co., St. Louis, Mo.
The results obtained are summarized in Tables 1 and 2 and Fig. 1 and 2 . When clarithromycin activity was screened against five strains of mycobactin-dependent M. paratuberculosis and compared with activities of six other drugs used in parallel (i.e., rifampin, ethambutol, amikacin, ofloxacin, ciprofloxacin, and sparfloxacin), clarithromycin MICs were lowest against all the strains, with MICs of 0.25 p,g/ml for four strains and 0.5 ,ug/ml for one strain. Origin of strains (type strain, livestock, or Crohn's disease isolates) did not change the overall drug susceptibility profile. The mycobactin dependence of all the M. paratuberculosis strains used in this study was verified by using solid growth media (results not shown) or radiometrically as illustrated in Fig. 1 .
When the enhancement of clarithromycin activity by ethambutol was measured by the X/Y quotient calculations, clarithromycin activity was enhanced in three out of four strains of M. paratuberculosis (Table 2 ). This drug enhancement effect was confirmed in the case of the ATCC 19698 strain by plating the cultures from Bactec vials for viable count determinations (Fig. 2A) . All the drugs in radiometric enhancement experiments were used at sub-MIC levels, i.e., 1 ,ug/ml for rifampin, ofloxacin, and ciprofloxacin; 0.25 ,ug/ml for amikacin and sparfloxacin; and 0.1 ,g/ml for clarithromycin. These results are in agreement with previously published data with MAC organisms (14, (16) (17) (18) .
When tested against M. paratuberculosis ATCC 19698 phagocytized by murine macrophages, clarithromycin used at its Cm. level of 4 ,ug/ml possessed significant bactericidal activity, as it was able to kill the initial inoculum by more than 1 log within 7 days, and this activity was further potentiated by ethambutol used at a Cm. level of 6 ,ug/ml (Fig. 2B) .
In summary, the results obtained showed that clarithromycin possessed promising in vitro MICs against both animal and human isolates of M. paratuberculosis, with significant bactericidal activity against intracellular bacteria. In agreement with our previous observations for M. avium (17), the present study showed that ethambutol was further able to enhance both the extracellular and intracellular activities of clarithromycin against M. paratuberculosis. Clarithromycin, therefore, may prove to be as effective in treating M. paratuberculosis infections as it was recently shown to be in treating M. avium-infected AIDS patients (4 
